SCHEMBL3382972

SCHEMBL3382972

CCOC(=O)Cc1nc2sc(C)c(-c3ccc(F)cc3)c2c(=O)[nH]1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.60
LMNA P02545 2/20 0.60
RXFP1 Q9HBX9 2/20 0.54
CYP1A1 P04798 1/20 0.47
KMT2A Q03164 3/20 0.46
HPGD P15428 4/20 0.46
KDM4E B2RXH2 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
SIRT5 Q9NXA8 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
MEN1 O00255 2/20 0.43
TSHR P16473 1/20 0.43
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HSD17B10 Q99714 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2369050 0.89 ALDH1A1 (0.74) ALDH1A1LMNARXFP1KMT2AHPGD
SCHEMBL2368352 0.82 ALDH1A1 (0.51) ALDH1A1LMNARXFP1KMT2AHPGD
SCHEMBL3387536 0.81 ALDH1A1 (0.66) ALDH1A1LMNARXFP1KMT2AHPGD
SCHEMBL652947 0.79 RAB9A (0.61) ALDH1A1KMT2AHPGDKDM4ESMN1; SMN2
SCHEMBL3386420 0.79 ALDH1A1 (0.45) ALDH1A1LMNAKMT2AHPGDKDM4E
SCHEMBL14875794 0.75 TYMS (0.65) ALDH1A1LMNARXFP1CYP1A1HPGD
SCHEMBL8203415 0.73 ALDH1A1 (0.66) ALDH1A1LMNARXFP1KMT2AHPGD
SCHEMBL4514873 0.70 KMT2A (0.67) ALDH1A1LMNARXFP1CYP1A1KMT2A
SCHEMBL2368236 0.70 ALDH1A1 (0.71) ALDH1A1LMNAKMT2AKDM4ESMN1; SMN2
SCHEMBL3387429 0.69 ALDH1A1 (0.51) ALDH1A1LMNAKMT2AHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 ALDH1A1 247/4885LMNA 1126/4885RXFP1 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.